Cerebral Microembolism During Hemodialysis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Dr. Gabor Erdoes, Medical University of Vienna
ClinicalTrials.gov Identifier:
First received: November 20, 2013
Last updated: October 5, 2015
Last verified: October 2015

There is increasing evidence that renal replacement therapy (= continuous veno-venous hemodialysis) generates cerebral microembolism which is detectable on transcranial Doppler ultrasound.

The aim of this study is to monitor patients with transcranial Doppler under two conditions: during hemodialysis and in a hemodialysis-free interval (in each period cerebral embolic load is detected during 30 minutes).

The study hypothesis is that during hemodialysis the cerebral embolic load is significantly higher than in the hemodialysis-free interval.

Condition Intervention
Complication of Dialysis
Thrombus Due to Renal Dialysis Device, Implant, or Graft
Cerebral Embolism
Device: Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Quantity, Quality and Laterality of Cerebral Microembolism During Veno-Venous Hemodialysis.

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Quantity of cerebral embolic load [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
    Cerebral embolic load is measured in a 30 minutes-interval during hemodialysis and in a hemodialysis-free interval.

Secondary Outcome Measures:
  • Quality and laterality of cerebral embolic load [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
    Quality (solid vs. gaseous) and laterality (left vs. right hemispheric dominance) of cerebral embolic load is measured in a 30 minutes-interval during hemodialysis and in a hemodialysis-free interval.

Estimated Enrollment: 20
Study Start Date: September 2013
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patient on Hemodialysis
Renal hemodialysis
Device: Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)
Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
Other Name: Continuous veno-venous hemodialysis
Patient in a hemodialysis-free interval
No Renal hemodialysis


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population incloses patients who are in renal failure needing renal replacement therapy under intensive care conditions.

Inclusion Criteria:

  • Renal replacement therapy (continuous veno-venous hemodilalysis) on the in-house intensive care unit
  • Age > 18yrs and < 90yrs

Exclusion Criteria:

  • Absent informed consent
  • Preexistent neurological morbidity
  • Neurocognitive disturbances
  • Carotid artery stenosis > 70%
  • Patent foramen ovale
  • Treatment with other extracorporeal devices
  • Cardial pathology (valvular heart disease, prosthesis, endocarditis)
  • Pregnancy, drug abuse
  • Inclusion in an other clinical study
  • Allergy against materials of the medical device used in the study (transcranial Doppler) or temporal skin/bone lesions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02021045

Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Gabor Erdoes, MD Medical University of Vienna
  More Information

No publications provided

Responsible Party: Dr. Gabor Erdoes, Dr Gabor Erdoes, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT02021045     History of Changes
Other Study ID Numbers: 1706/2013
Study First Received: November 20, 2013
Last Updated: October 5, 2015
Health Authority: Austria: Ethikkommission

ClinicalTrials.gov processed this record on November 27, 2015